Homocysteine affects macrophage polarization by altering m6A methylation of scavenger receptors CD209 and CD163L1 Authors: Yu Liang, Yongbo Wang, Jia Tan, Jingxuan Shu, Ya Xu, Mingyuan Wang, Shengjun Yang, Linna Ma Published: 2024 ABSTRACT ABSTRACTAtherosclerosis is a chronic inflammatory disease characterized by fatty plaque deposits on artery walls. Elevated plasma homocysteine (Hcy) levels are an independent risk factor for atherosclerosis. Research on the mechanism by which Hcy promotes atherosclerosis has gradually turned to epigenetic inheritance, but the correlation between Hcy and m6A (N6-methyladenosine) modification has not been reported. In this study, MeRIP-seq was performed on macrophages and Hcy-treated macrophages. GO and KEGG analyses were used to perform functional analysis of differentially methylated genes. qRT-PCR and western blot were taken to determine the expression of CD209, CD163L1, proinflammatory, and anti-inflammatory factors. Flow cytometry was used to detect the proportion of M2 macrophages. The results showed that after Hcy treatment, the overall m6A methylation of macrophages was down-regulated, and 856 differential methylation peaks were annotated to 781 genes. These included CD209 and CD163L1, whose m6A methylation was inhibited after treatment with Hcy. In addition, mRNA and protein expressions of CD209 and CD163L1 were also inhibited after Hcy treatment. Overexpression of CD209 or CD163L1 prevents the Hcy-induced decrease in the proportion of M2 macrophages. This article identified changes in the modification level of m6A in macrophages by Hcy and revealed the possible mechanism by which Hcy induces macrophage polarization.KEYWORDS: Atherosclerosis, homocysteine, m6A methylation, CD209, CD163L1 Introduction Hcy is an intermediate product of methionine metabolism. Hyperhomocysteinemia (HHcy), a pathological condition associated with the dysregulation of lipid metabolism, is recognized as an independent risk factor for atherosclerosis (AS) [1]. t has been reported that the activation of the immune inflammatory response is a key initiator of AS, with macrophages playing a crucial role in this process [2,3]. Macrophages can polarize into M1 and M2 types in response to microenvironmental stimuli. The M1 phenotype, which has a pro-inflammatory role, promotes the development of AS, whereas the M2 phenotype, which has an anti-inflammatory role, suppresses AS progression [4]. Hcy has been shown to induce macrophages to polarize towards the M1 pro-inflammatory phenotype [5,6], representing one of the mechanisms by which it promotes AS. Scavenger receptors (SRs), initially identified as cell surface receptors that recognize and bind oxidized low-density lipoprotein (ox-LDL), have recently been shown to accelerate the progression of atherosclerosis by inducing the formation of foam macrophages through enhanced lipoprotein uptake [7–9]. Furthermore, SRs have been implicated in inflammatory responses associated with disease by modulating macrophage polarization. Specifically, SR-A1 has been associated with the anti-inflammatory response by promoting the M2 macrophage phenotype in the context of cardiovascular disease [8], while CD163 has been shown to inhibit the lipopolysaccharide-induced transition of macrophages from the M2 to M1 phenotype [10]. Nevertheless, the mechanisms regulating the expression of SRs in macrophages remain incompletely understood and warrant further investigation. Previous research has indicated that Hcy up-regulates the expression of the scavenger receptor CD36 [11], thereby inducing foam cell formation and promoting the progression of AS. Additionally, LOX-1, a member of the scavenger receptor family that facilitates foam cell formation, has been shown to reduce DNA methylation levels while up-regulating both mRNA and protein expression in response to Hcy treatment [12]. In recent years, the focus of atherosclerosis research has shifted from genetic regulation to epigenetic regulation. Given that Hcy serves as a precursor to S-adenosylmethionine (SAM) and acts as the primary methyl donor for most biological methylation processes, its impact on methylation levels has emerged as a new area of study in the development of AS [13–16]. Currently, there are no studies examining the effects of Hcy on macrophage polarization through the regulation of m6A modification. The purpose of this study was to investigate the effect of Hcy on the methylation levels of m6A in macrophages using MeRIP-seq technology. Additionally, the study aimed to explore whether Hcy influences the expression of SRs by altering the methylation levels of these receptors, thereby affecting macrophage polarization. Materials & methods Cell culture and treatment THP-1 cells purchased from the Chinese Academy of Sciences cell bank were cultured in RPMI (Gibco, USA) medium containing 10% fetal bovine serum (FBS; Gibco, USA) at 37°C in a humidified environment with 5% CO2. Initially, cells were differentiated into macrophages by the addition of 5 mm phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, USA) for 48 hours. Macrophages were then treated with 100 μM Hcy (Sigma-Aldrich, USA). In our experiments, macrophages served as control cells (Group A) and Hcy-treated cells as treated cells (Group B). Methylated RNA immunoprecipitation sequencing (MeRIP-seq) The mRNA enriched by Oligo d(T) magnetic beads was broken into fragments of about 100 bp and immunoprecipitated with m6A antibody. One-stranded cDNA was synthesized using immunoprecipitated pulldown RNA as a template with a six-base random primer. Specific junctions are attached to both ends of the DNA and subsequently purified with magnetic beads. The quality inspection results of agarose electrophoresis and the quantitative results of Qubit 3.0 determine whether the constructed library is suitable for machine detection. After passing the quality inspection, different libraries were sequenced according to the effective concentration. MeRIP-seq data analysis After obtaining raw data, the raw data is first filtered to obtain high-quality sequencing data. Clean data was compared to the reference genome of the project species to obtain comprehensive transcript information, and gene expression quantification was performed. Meanwhile, the results were compared by genome-wide de novo peak calling to study the binding preference of proteins on RNA, and motif analysis of binding sites was conducted. Gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and genomes (KEGG) analysis GO analysis (http://www.geneontology.org) was used to classify and annotate genes in three aspects: biological process, molecular function, and cell component. The KEGG (http://www.genome.jp/kegg/) database identifies biochemical metabolic and signaling pathways in which differential genes are primarily involved by pathway significance enrichment. Real-time quantitative PCR Total RNA from the cells was extracted using TRIzol reagent (Takara, Japan). Subsequently, the RNA was reverse transcribed into cDNA by PrimeScript™ FAST RT reagent Kit (Takara, Japan). The reaction system was prepared according to the TB Green® Premix Ex Taq™ II FAST qPCR (Takara, Japan) instructions. Quantitative primers were synthesized by Qing Ke Biologicals. Western blot Cells were lysed on ice using RIPA Lysis Buffer (Beyotime, China) -and protease inhibitors (Beyotime, China) to extract total protein. The samples were isolated by SDS-PAGE (GenScript, China) and transferred to a polypropylene fluoride membrane (Millipore, Germany). The membrane was blocked with 5% bovine serum albumin for 2 h at room temperature. After overnight incubation of the primary antibody at 4°C, the secondary antibody was incubated at room temperature for 2 h. After TBST washing, the ECL luminescence kit displayed the image, the chemiluminescence instrument captured the bands, and Image J software quantified the protein bands. Primary antibody: β-actin(1:2000; Abcam, USA), CD209 (1:2000; Invitrogen, USA), CD163L1 (1:2000; Invitrogen, USA), CD86 (1:1000; Cell Signaling, USA), CD206 (1:1000; Cell Signaling, USA), iNOS (1:1000; Cell Signaling, USA), Arg-1 (1:1000; Cell Signaling, USA). Second antibody: Goat Anti-Rabbit IgG H&L (HRP)(1:10000; Abcam, USA). Plasmids construct The coding sequences(CDS) of CD209 and CD163L1 was amplified by PCR. After the PCR product and pcDNA3.1 vector were cut by restriction enzyme, the two were linked with T4 ligase (Thermo Fisher, USA). The conjugated products were transformed into DH5α receptor cells (Qinke, China) and cultured in Luria-Bertani medium at 37°C for 2 h. 250 µl bacterial solution was coated, and incubated at 37°C overnight, and monoclonal was selected. A Plasmid Mini Kit I (Omega, USA) was used to extract the plasmid after amplification and culture. Flow cytometric analysis CD68 was selected as Macrophage markers, and CD206 was selected as phenotypic markers of M2 macrophage. PE-conjugate CD68 and FITC-conjugate CD206 antibodies(Biolegend, USA) were incubated with cells at 4°C for 30 min. 10000 cell counts were collected for each sample using the BD FACSCalibur system (BD Biosciences, San Diego, CA) and the data were analysed using FlowJo software (Tree Star, Ashland, OR). Statistical analysis Data analysis was calculated using SPSS software, and bar charts were drawn using Prism 9.0. The results were presented as mean ±SEM. Statistical significance was calculated using a two-tailed Student’s t-test. p < 0.05 is considered significant. Results Methylation levels of the genome and identification of differential methylation regions To investigate the effect of Hcy on m6A methylation modification in macrophages, MeRIP-seq was conducted for macrophages and Hcy-treated macrophages. The m6A antibody-enriched RNA sequences were directly sequenced by high-throughput sequencing, and peak calling was performed using exomePeak. The results of MeRIP-seq revealed 12,211 methylation peaks in the control group and 11,845 peaks in the Hcy-treated group (Figure 1a). The above data showed that Hcy treatment reduced the total methylation level of macrophage. No significant differences were found between the two groups’ length of methylated regions (Figure 1b). Consistent with previous reports, the m6A methylation regions were mainly located near the stop codon and 3’UTR of the mRNA transcript (Figure 1c,d). QNB software was used to identify the differential methylation peaks between the control group and the Hcy-treated group. Differential methylation peaks were calculated according to the principle of difference multiple > 2 and p value < 0.05. The heat map and volcanic maps showed that a total of 856 differential methylation peaks were identified, including 346 hypermethylation peaks and 510 hypomethylation peaks (Figure 1e,f). Statistics of genomic methylation regions and identification of differential methylation regions. (a) The number of methylation peaks in groups A and B. (b) The length of the methylation peak region in groups A and B. (c & d) distribution of the methylation peak region on the mRNA transcript of groups A and B. (e & f) heat map and volcano plot showing the most significant differential methylation regions between group A and B, |log2(fold change) |> 1 and p-value < 0.05. Group A: control group; Group B: Hcy-treated group. Functional enrichment of genes annotated by differential methylation peaks Differential methylation peaks were annotated to genes, A total of 856 differential methylation peaks were annotated to 781 genes, some of which contained more than 1 methylation peak. GO analysis indicated that the cardiomyocyte apoptosis process and negative regulation of mitochondrial autophagy had the highest enrichment level (Figure 2a), and the number of genes enriched in the nucleus, cytosol, and nucleoplasm-related cell components was the highest (Figure 2b). KEGG analysis indicated that differentially methylated genes are primarily enriched in mitophagy and autophagy pathways (Figure 3c). Enrichment analysis of differentially methylated genes. (a) The GO analysis bubble map of differential methylation genes. (b) The GO analysis histogram of differential methylation genes. (c) The KEGG pathway enrichment bubble map of differential methylation genes. Hcy regulates m6A methylation of SRs and genes associated with atherosclerosis. (a) Data on SRs and atherosclerosis-related genes undergoing m6A modification in groups A and B. (b) Overlapping genes of differentially methylated genes with SRs, atherosclerosis-related genes. (c) GO analysis of methylated differential genes in SRs. (d) GO analysis of atherosclerosis-associated methylated differential genes. Hcy regulates m6A methylation of SRs and genes associated with atherosclerosis The scavenger receptor (SR) family is a kind of macrophage surface receptor, which is the main pathway mediating the uptake of ox-LDL by macrophages and an important factor affecting the inflammatory response of macrophages. To investigate whether Hcy promotes atherosclerosis by regulating m6A methylation of SRs and atherosclerosis-related genes, genes annotated by Group A and Group B methylation peaks overlapped with SRs and atherosclerosis-related genes, respectively. m6A methylation was observed in 8 SRs and 66 atherosclerosis-related genes in Group A, and 9 SRs and 58 atherosclerosis-related genes in Group B (Figure 3a). The differential methylation genes in groups A and B were then overlapped with SRs and atherosclerosis-related genes. The Venn diagram showed that the m6A methylation modification levels of 2 SRs genes and 9 atherosclerosis-related genes were changed after Hcy treatment (Figure 3b). Consistent with the function of SR as a cell surface receptor, GO analysis showed that the two differentially methylated SRs were mainly enriched in the biological process of endocytosis (Figure 3c). Differential methylation genes associated with atherosclerosis were primarily enriched in the methionine biosynthetic process (Figure 3d). It has been widely reported that methionine can be activated to S-adenosylmethionine to provide methyl groups for methylation modification. Therefore, the GO analysis results further verified that m6A methylation modification is an important epigenetic regulator of Hcy-promoting atherosclerosis. Hcy inhibits CD209 and CD163L1 expression by regulating m6A modifications MeRIP-seq results indicated that SR family members CD209 and CD163L1 undergo changes in m6A methylation levels upon Hcy treatment. To verify whether Hcy regulates m6A modification-mediated expression of CD209 and CD163L1, we examined the expression levels of CD209 and CD163L1 after treatment with Hcy. qPCR and western blot results showed that Hcy treatment significantly down-regulated the mRNA and protein expression of CD209 and CD163L1 (Figure 4a and 4b). Taken together, Hcy inhibits the expression of CD209 and CD163L1 by regulating m6A methylation modifications. Hcy inhibits CD209 and CD163L1 expression by regulating m6A methylation modifications. (A) mRNA expression levels of CD209 and CD163L1 after hcy treatment of macrophage. (B) Protein expression levels of CD209 and CD163L1 after hcy treatment of macrophage. *p < 0.05; **p < 0.01. Hcy promotes macrophage differentiation into M1 by regulating the expression of CD209 and CD163L1 It has been reported that Hcy can induce macrophage differentiation in the M1 direction, and inhibit macrophage differentiation in the M2 direction. To further investigate whether Hcy altered the immunophenotype by regulating the expression of CD209 and CD163L1, macrophages were treated with Hcy while CD209 or CD163L1 was overexpressed. The mRNA expressions of CD209 and CD163L1 were significantly up-regulated after transfection with overexpressed plasmids (Figure 5a). Hcy treatment of macrophages while transfected with pcDNA3.1-CD209 or pcDNA3.1-CD163L1 blocked Hcy-induced inhibition of CD209 or CD163L1 expression (Figures 5a). Hcy treatment up-regulated mRNA expression of pro-inflammatory factors INF-γ, IL-1β, and IL-6 (Figure 5c) and down-regulated mRNA expression of anti-inflammatory factors IL-10, TGF-β1, and IL-13 (Figure 5d), which was reversed by overexpression of CD209 or CD163L1. The same situation also occurred in the protein expressions of M1 differentiation-related markers CD86, iNOS, and M2 differentiation-related markers CD206 and Arg-1 (Figure 5e). Flow cytometry showed that Hcy treatment decreased the proportion of M2 macrophages. Similarly, overexpression of CD209 or CD163L1 increased the proportion of M2 macrophages. (Figure 5f). Hcy promotes macrophage differentiation into M1 by regulating the expression of CD209 and CD163L1. (a) Efficiency of CD209 and CD163L1 overexpression. (b) Protein expression of CD209 and CD163L1 in macrophage cells of each treatment group. (c) mRNA expression of pro-inflammatory and anti-inflammatory in each treatment group. (d) mRNA expression of anti-inflammatory in each treatment group. (e) protein expression of M1 and M2 macrophage markers in each treatment group. (f) The proportion of M2 macrophages was measured by flow cytometry. *p < 0.05; **p < 0.01. Discussion Hcy has been widely recognized as an independent risk factor for atherosclerosis [17]. As Hcy is produced during the methionine cycle and serves as a key intermediate metabolite in the methylation reaction, an increasing number of studies have investigated how Hcy accelerates the progression of atherosclerosis by influencing methylation levels. In the study conducted by Shengchao Ma et al., Hcy was found to promote oxidative stress in atherosclerosis by regulating the DNA methylation of extracellular superoxide dismutase [13]. Additionally, Hcy contributed to the progression of atherosclerosis by increasing DNA methylation in the promoter region of miR-124 [18]. Consistent with these findings, numerous studies have demonstrated that Hcy promotes disease progression through the regulation of DNA methylation modifications; however, there are relatively few reports on the correlation between Hcy and m6A methylation. In this study, we discovered that Hcy treatment-induced changes in m6A methylation in 781 genes in macrophages through MeRIP-seq analysis. Inflammation and the formation of foam cells are primary processes that accelerate the progression of atherosclerosis. Recent studies have demonstrated that macrophage polarization plays a crucial role in regulating inflammatory responses [19,20]. Generally, macrophages can be categorized into two main phenotypes: classically activated pro-inflammatory M1 macrophages and selectively activated anti-inflammatory M2 macrophages. M1 cells secrete a substantial quantity of pro-inflammatory factors that stimulate the cellular immune response [21], while M2 cells release a variety of anti-inflammatory factors that promote cellular stability and tissue healing [22]. Consequently, M1 macrophages contribute to the development of unstable atherosclerotic plaques, whereas M2 macrophages facilitate the formation of stable atherosclerotic plaques. The immunophenotypes of macrophages change in response to varying microenvironments. Previous studies have demonstrated that Hcy treatment induces the polarization of M1 macrophages [6,23,24], increases the release of pro-inflammatory factors, and exacerbates the inflammatory response; however, the precise mechanism remains unclear. Macrophages express a variety of scavenger receptor family members, such as SR-A1, CD36, and LOX-1, which facilitate the formation of foam macrophages by promoting the uptake of LDL and the deposition of cholesterol, thereby accelerating the progression of atherosclerosis [7,25,26]. Furthermore, scavenger receptors SR-A1 and CD163 have been shown to regulate macrophage polarization [8,10,27]. Previous research has indicated that changes in DNA methylation levels are one of the mechanisms through which Hcy regulates scavenger receptors [12]. In this study, we aimed to investigate whether Hcy alters the m6A methylation of specific scavenger receptors to regulate their expression, subsequently affecting macrophage phenotype. By screening genes that exhibited differential methylation following Hcy treatment, we identified that the m6A methylation levels of scavenger receptor family members CD209 and CD163 were altered. Concurrently, our in vitro experimental results demonstrated that Hcy inhibited the mRNA and protein expression of both Dendritic cell-specific ICAM-3 grabbing non-integrin (CD209) and CD163 molecule-like 1 (CD163L1). CD209 has been widely recognized as an M2 macrophage marker. The expression of CD209 was upregulated in the induction of macrophage M2 polarization by interleukin 4 (IL-4) and macrophage colony-stimulating factor (M-SF). Moreover, the ligation of CD209 on the cell surface inhibited the production of proinflammatory cytokines [28]. CD163L1 is a scavenger receptor on the surface of macrophages, and macrophages expressing CD163L1 exhibit an M2 phenotype. Expression of CD163L1 is increased when monocytes are stimulated by M-SF to differentiate into M2 macrophages [29]. The expression of CD163L1 was increased by the anti-inflammatory mediator IL-10 and suppressed by the pro-inflammatory mediators IL-4, IL-13, TNF-α, and LPS/IFN-γ [30]. Hcy treatment was found to enhance the expression of pro-inflammatory factors and markers associated with M1 macrophage differentiation, while simultaneously inhibiting the expression of anti-inflammatory factors and markers related to M2 macrophage differentiation, resulting in a reduced proportion of M2 macrophages. However, the overexpression of CD209 or CD163L1 during Hcy treatment reversed this trend. This suggests that when the expression of CD209 and CD163L1 is not inhibited by Hcy, the inflammatory response induced by Hcy is weakened. In other words, Hcy may influence macrophage phenotypes in part by regulating the expression of CD209 and CD163L1. In this study, we used MeRIP-seq to screen out the scavenger receptors CD209 and CD163L1, whose m6A modifications were altered after Hcy treatment and verified that their expression was regulated by Hcy. In addition, in vitro experiments confirmed that Hcy may promote the polarization of macrophages towards M1 by regulating CD209 and CD163L1. However, we acknowledge that the study has some limitations. First of all, due to existing conditions, we used THP-1 cells instead of primary macrophages as the study model in vitro. Indeed, although THP-1 has been widely used as an in vitro model system for macrophage differentiation and function studies, primary macrophages are closer to the real conditions of our study and better strengthen our findings. Therefore, we will further prove our conclusions on primary macrophages as much as possible in the future. Secondly, Hcy is an important risk factor for AS, SRs are also an important cell surface receptor that affects the development of AS, and macrophage polarization has also been reported to be involved in AS. We only focused on the mechanism of Hcy inducing macrophage polarization by altering the m6A modification of SRs in this paper, and no in vivo experiments were performed, further studies are needed to provide a more comprehensive insight under pathological conditions. Conclusion We demonstrated for the first time that Hcy can affect m6A modification in macrophages using MeRIP-seq. In addition, we reveal the mechanism by which Hcy affects macrophage polarization by altering m6A levels of CD209 and CD163L1 in SR family members. Funding Statement The work was supported by the General Joint Project of the Department of Science and Technology of Yunnan Province and Kunming Medical University [202301AY070001–144]; the Applied Basic Research Project of Yunnan Province [202301AY070001–144]; First People’s Hospital of Yunnan Province High-level Talent Subsidy Program [2022-KHRCBZ-B02]. Disclosure statement No potential conflict of interest was reported by the author(s). Author contributions YL and LM designed the study. YWH analysed the sequencing data. YL, JT and YX conducted experiments. MW and SY organized and arranged all the figures.YL and YWH prepared and wrote the original draft of the manuscript. XN reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version. Data availability statement The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.